This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment
BMC Cancer Open Access 12 February 2016
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Thomas J, Wang L, Clark RE, Pirmohamed M . Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004; 104: 3739–3745.
Marin D, Bazeos A, Mahon F-X, Eliason L, Milojkovic D, Bua M et al. Adherence is the critical factor for achieving molecular responses in chronic myeloid leukemia patients who achieve complete cytogenetic responses on imatinib. J Clin Oncol; e-pub ahead of print 12 April 2010.
Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE . Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008; 83: 258–264.
Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE . hOCT 1 and resistance to imatinib. Blood 2005; 106: 1133–1134.
Zhang WW, Cortes JE, Yao H, Zhang L, Reddy NG, Jabbour E et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J Clin Oncol 2009; 27: 3642–3649.
Gaiger A, Henn T, Horth E, Geissler K, Mitterbauer G, Maier-Dobersberger T et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995; 86: 2371–2378.
Kim DH, Xu W, Ma C, Liu X, Siminovitch K, Messner HA et al. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood 2009; 113: 2517–2525.
Shu Y, Brown C, Castro RA, Shi RJ, Lin ET, Owen RP et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther 2008; 83: 273–280.
D Marin, JF Apperley, JM Goldman, D Milojkovic and K Rezvani receive honoraria and/or research funds from Novartis Pharmaceuticals. However, Novartis had no role in the design of the study, collection of the data or the decision to publish.
About this article
Cite this article
Bazeos, A., Marin, D., Reid, A. et al. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia. Leukemia 24, 1243–1245 (2010). https://doi.org/10.1038/leu.2010.86
This article is cited by
OCT-1 Expression in Patients with Chronic Myeloid Leukemia: A Comparative Analysis with Respect to Response to Imatinib Treatment
Indian Journal of Hematology and Blood Transfusion (2022)
Genetic variations in influx transporter gene SLC22A1 are associated with clinical responses to imatinib mesylate among Malaysian chronic myeloid leukaemia patients
Journal of Genetics (2018)
Pathology & Oncology Research (2017)
Molecular Diagnosis & Therapy (2017)
hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia
Cancer Chemotherapy and Pharmacology (2017)